Ajanta Pharma has reported strong consolidated financial results for the fourth quarter and full year ended March 31, 2026, driven by robust growth across its domestic and international businesses.

For Q4 FY26, the company’s revenue from operations rose 21% year-on-year to Rs 1,422 crore compared to Rs 1,170 crore in the corresponding quarter last year. Profit after tax (PAT) increased 18% to Rs 267 crore, while EBITDA stood at Rs 333 crore with an EBITDA margin of 23%.

Ajanta Pharma said the quarter was impacted by a mark-to-market forex loss of Rs 42 crore. Excluding this impact, adjusted EBITDA rose 26% to Rs 375 crore, with adjusted EBITDA margin improving to 26%.

For the full financial year FY26, revenue from operations grew 17% to Rs 5,453 crore, while PAT rose 15% to Rs 1,056 crore. EBITDA for the year stood at Rs 1,395 crore, with adjusted EBITDA reaching Rs 1,498 crore after excluding forex losses. The company reported a Return on Capital Employed (ROCE) of 33% and Return on Net Worth (RONW) of 25%.

Segment-wise, the company’s US generics business emerged as a major growth driver, recording a 56% increase in Q4 revenue to Rs 505 crore and a 49% rise in FY26 revenue to Rs 1,557 crore. Branded generics across India, Asia, and Africa collectively contributed Rs 859 crore during the quarter.

Ajanta Pharma also continued to strengthen its research and development pipeline. The company spent approximately 5% of its revenue on R&D during FY26 and currently has multiple ANDA filings awaiting approval from the US FDA.

Additionally, the company informed stock exchanges that the audio recording of its Q4 FY26 earnings call held on May 5, 2026, has been uploaded to its website in compliance with SEBI regulations.